SODIUM POLYSTYRENE SULFONATE
Details
- Status
- Prescription
- First Approved
- 1984-09-11
- Routes
- ORAL, RECTAL
- Dosage Forms
- POWDER, SUSPENSION
Companies
SODIUM POLYSTYRENE SULFONATE Approval History
What SODIUM POLYSTYRENE SULFONATE Treats
1 indicationsSODIUM POLYSTYRENE SULFONATE is approved for 1 conditions since its original approval in 1984. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Hyperkalemia
Drugs Similar to SODIUM POLYSTYRENE SULFONATE
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
SODIUM POLYSTYRENE SULFONATE FDA Label Details
ProIndications & Usage
Sodium polystyrene sulfonate for suspension is indicated for the treatment of hyperkalemia. Limitation of Use : Sodium polystyrene sulfonate for suspension should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see Clinical Pharmacology ] Sodium polystyrene sulfonate for suspension is a potassium binder indicated for the treatment of hyperkalemia . Limitation of Use : Sodium polystyrene sulfonate for suspension should not be used an emergency treatment for life threatening hyperkalemia because of its delayed onset of action .
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.